New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
08:44 EDTMGNXMacroGenics reports milestone in DART program triggers $20M in payments
MacroGenics announced that Servier, France's largest privately-held pharmaceutical company, has exercised its exclusive option to develop and commercialize MGD006, a DART-based product candidate developed by MacroGenics. Servier will gain exclusive development and commercial rights in all countries outside of the U.S., Canada, Mexico, Japan, South Korea and India. In those countries, MacroGenics will retain development and commercialization rights. As a result of the exercise, MacroGenics will receive a $15M payment from Servier. In addition, the Investigational New Drug application for MGD006 has cleared the 30 day review period by the U.S. Food and Drug Administration, triggering an additional $5M payment to MacroGenics by Servier.
News For MGNX From The Last 14 Days
Check below for free stories on MGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for MGNX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use